Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Clinical and Experimental Nephrology
Erschienen in: Clinical and Experimental Nephrology 6/2014

01.12.2014 | Review Article

An update for the controversies and hypotheses of regulating nonthyroidal illness syndrome in chronic kidney diseases

Erschienen in: Clinical and Experimental Nephrology | Ausgabe 6/2014

Einloggen, um Zugang zu erhalten

Abstract

Nonthyroidal illness syndrome (NTIS) is widely found in the patients with chronic kidney disease (CKD) or critical illness. However, the exact pathogenesis and reasonable treatment remain unclear. To identify suitable studies for inclusion in present review, a search for articles using PubMed search engine with combined terms: (thyroid OR hypothyroidism OR hyperthyroidism OR triiodothyronine) AND (glomerulonephritis OR chronic kidney disease OR chronic renal failure OR end stage renal disease OR hemodialysis OR peritoneal dialysis OR kidney transplantation OR renal transplantation) was performed. The bibliographies of relevant articles were also hand searched. The search was updated on November 8, 2013. Mechanisms for the alternations of thyroid hormone concentrations in NTIS are complicated. Inflammatory cytokines and oxidative stress may play pivotal roles in the pathogenesis of NTIS in patients with CKD. It was controversial whether CKD patients with NTIS should be treated with thyroid hormone replacement. N-Acetyl cysteine or sodium bicarbonate may negatively regulate the progress of micro-inflammation in CKD. Large-scale, multi-centered randomized controlled trials should be conducted to verify the NTIS hypothesis in CKD patients.
Literatur
1.
Docter R, Krenning EP, de Jong M, Hennemann G. The sick euthyroid syndrome: changes in thyroid hormone serum parameters and hormone metabolism. Clin Endocrinol (Oxf). 1993;39(5):499–518.CrossRef
2.
Lo JC, Chertow GM, Go AS, Hsu CY. Increased prevalence of subclinical and clinical hypothyroidism in persons with chronic kidney disease. Kidney Int. 2005;67(3):1047–52.PubMedCrossRef
3.
Silverberg DS, Ulan RA, Fawcett DM, Dossetor JB, Grace M, Bettcher K. Effects of chronic hemodialysis on thyroid function in chronic renal failure. Can Med Assoc J. 1973;109(4):282–6.PubMedCentralPubMed
4.
Kang EW, Nam JY, Yoo TH, Shin SK, Kang SW, Han DS, et al. Clinical implications of subclinical hypothyroidism in continuous ambulatory peritoneal dialysis patients. Am J Nephrol. 2008;28(6):908–13.PubMedCrossRef
5.
6.
Attia J, Margetts P, Guyatt G. Diagnosis of thyroid disease in hospitalized patients: a systematic review. Arch Intern Med. 1999;159(7):658–65.PubMedCrossRef
7.
De Groot LJ. Dangerous dogmas in medicine: the nonthyroidal illness syndrome. J Clin Endocrinol Metab. 1999;84(1):151–64.PubMedCrossRef
8.
Boelen A, Kwakkel J, Platvoet-ter Schiphorst M, Baur A, Köhrle J, Wiersinga WM. Contribution of interleukin-12 to the pathogenesis of non-thyroidal illness. Horm Metab Res. 2004;36(2):101–6.PubMedCrossRef
9.
Angelousi AG, Karageorgopoulos DE, Kapaskelis AM, Falagas ME. Association between thyroid function tests at baseline and the outcome of patients with sepsis or septic shock: a systematic review. Eur J Endocrinol. 2011;164(2):147–55.PubMedCrossRef
10.
Amato AA, Santos GM, Neves Fde A. Thyroid hormone action in chronic kidney disease. Curr Opin Endocrinol Diabetes Obes. 2008;15(5):459–65.PubMedCrossRef
11.
Mehta HJ, Joseph LJ, Desai KB, Mehta MN, Samuel AM, Almeida AF, et al. Total and free thyroid hormone levels in chronic renal failure. J Postgrad Med. 1991;37(2):79–83.PubMed
12.
Enia G, Panuccio V, Cutrupi S, Pizzini P, Tripepi G, Mallamaci F, et al. Subclinical hypothyroidism is linked to micro-inflammation and predicts death in continuous ambulatory peritoneal dialysis. Nephrol Dial Transpl. 2007;22(2):538–44.CrossRef
13.
Zoccali C, Tripepi G, Cutrupi S, Pizzini P, Mallamaci F. Low triiodothyronine: a new facet of inflammation in end-stage renal disease. J Am Soc Nephrol. 2005;16:2789–95.PubMedCrossRef
14.
Rotondi M, Netti GS, Rosati A, Mazzinghi B, Magri F, Ronconi E, et al. Pretransplant serum FT3 levels in kidney graft recipients are useful for identifying patients with higher risk for graft failure. Clin Endocrinol (Oxf). 2008;68(2):220–5.
15.
Pingitore A, Landi P, Taddei MC, Ripoli A, L’Abbate A, Iervasi G. Triiodothyronine levels for risk stratification of patients with chronic heart failure. Am J Med. 2005;118(2):132–6.PubMedCrossRef
16.
Frey A, Kroiss M, Berliner D, Seifert M, Allolio B, Güder G, et al. Prognostic impact of subclinical thyroid dysfunction in heart failure. Int J Cardiol. 2012;168(1):300–5.PubMedCrossRef
17.
Horáček J, Dusilová Sulková S, Kubišová M, Safránek R, Malířová E, et al. Thyroid hormone abnormalities in hemodialyzed patients: low triiodothyronine as well as high reverse triiodothyronine are associated with increased mortality. Physiol Res. 2012;61(5):495–501.PubMed
18.
Zoccali C, Mallamaci F, Tripepi G, Cutrupi S, Pizzini P. Low triiodothyronine and survival in end-stage renal disease. Kidney Int. 2006;70(3):523–8.PubMedCrossRef
19.
Jakobs TC, Schmutzler C, Meissner J, Köhrle J. The promoter of the human type I 5′-deiodinase gene––mapping of the transcription start site and identification of a DR+4 thyroid-hormone-responsive element. Eur J Biochem. 1997;247(1):288–97.PubMedCrossRef
20.
Burmeister LA, Pachucki J, St Germain DL. Thyroid hormones inhibit type 2 iodothyronine deiodinase in the rat cerebral cortex by both pre- and posttranslational mechanisms. Endocrinology. 1997;138(12):5231–7.PubMed
21.
Novitzky D, Cooper DK, Morrell D, Isaacs S. Change from aerobic to anaerobic metabolism after brain death, and reversal following triiodothyronine therapy. Transplantation. 1988;45(1):32–6.PubMedCrossRef
22.
Gereben B, Zeöld A, Dentice M, Salvatore D, Bianco AC. Activation and inactivation of thyroid hormone by deiodinases: local action with general consequences. Cell Mol Life Sci. 2008;65(4):570–90.PubMedCrossRef
23.
Coppola A, Liu ZW, Andrews ZB, Paradis E, Roy MC, Friedman JM, et al. A central thermogenic-like mechanism in feeding regulation: an interplay between arcuate nucleus T3 and UCP2. Cell Metab. 2007;5(1):21–33.PubMedCentralPubMedCrossRef
24.
Boelen A, Kwakkel J, Wiersinga WM, Fliers E. Chronic local inflammation in mice results in decreased TRH and type 3 deiodinase mRNA expression in the hypothalamic paraventricular nucleus independently of diminished food intake. J Endocrinol. 2006;191(3):707–14.PubMedCrossRef
25.
Zeöld A, Doleschall M, Haffner MC, Capelo LP, Menyhért J, Liposits Z, et al. Characterization of the nuclear factor-κB responsiveness of the human dio2 gene. Endocrinology. 2006;147(9):4419–29.PubMedCrossRef
26.
Farwell AP. Nonthyroidal illness syndrome. Curr Opin Endocrinol Diabetes Obes. 2013;20(5):478–84.PubMedCrossRef
27.
Crowley WF Jr, Ridgway EC, Bough EW, Francis GS, Daniels GH, Kourides IA, et al. Noninvasive evaluation of cardiac function in hypothyroidism. Response to gradual thyroxine replacement. N Engl J Med. 1977;296(1):1–6.PubMedCrossRef
28.
Klein I, Ojamaa K. Thyroid hormone and the cardiovascular system. N Engl J Med. 2001;344(7):501–9.PubMedCrossRef
29.
Schmid C, Brändle M, Zwimpfer C, Zapf J, Wiesli P. Effect of thyroxine replacement on creatinine, insulin-like growth factor 1, acid-labile subunit, and vascular endothelial growth factor. Clin Chem. 2004;50(1):228–31.PubMedCrossRef
30.
Diekman MJ, Harms MP, Endert E, Wieling W, Wiersinga WM. Endocrine factors related to changes in total peripheral vascular resistance after treatment of thyrotoxic and hypothyroid patients. Eur J Endocrinol. 2001;144(4):339–46.PubMedCrossRef
31.
Singer MA. Of mice and men and elephants: metabolic rate sets glomerular filtration rate. Am J Kidney Dis. 2001;37(1):164–78.PubMedCrossRef
32.
Napoli R, Guardasole V, Angelini V, Zarra E, Terracciano D, D’Anna C, et al. Acute effects of triiodothyronine on endothelial function in human subjects. J Clin Endocrinol Metab. 2007;92(1):250–4.PubMedCrossRef
33.
Bradley SE, Coelho JB, Sealey JE, Edwards KD, Stéphan F. Changes in glomerulotubular dimensions, single nephron glomerular filtration rates and the renin-angiotensin system in hypothyroid rats. Life Sci. 1982;30(7–8):633–9.PubMedCrossRef
34.
Feinstein EI, Kaptein EM, Nicoloff JT, Massry SG. Thyroid function in patients with nephrotic syndrome and normal renal function. Am J Nephrol. 1982;2(2):70–6.PubMedCrossRef
35.
Ramirez G, O’Neill W Jr, Jubiz W, Bloomer HA. Thyroid dysfunction in uremia: evidence for thyroid and hypophyseal abnormalities. Ann Intern Med. 1976;84:672–6.PubMedCrossRef
36.
Zeraati AA, Layegh P, Famili Y, Naghibi M, Sharifipour F, Shariati Sarabi Z. Serum triiodothyronine level as an indicator of inflammation in patients undergoing dialysis. Iran J Kidney Dis. 2011;5(1):38–44.PubMed
37.
38.
Bando Y, Ushiogi Y, Okafuji K, Toya D, Tanaka N, Miura S. Non-autoimmune primary hypothyroidism in diabetic and non-diabetic chronic renal dysfunction. Exp Clin Endocrinol Diabetes. 2002;110:408–15.PubMedCrossRef
39.
Boelen A, Maas MA, Lowik CW, Platvoet MC, Wiersinga WM. Induced illness in interleukin-6 (IL-6) knock-out mice: a causal role of IL-6 in the development of the low 3,5,3′-triiodothyronine syndrome. Endocrinology. 1996;137(12):5250–4.PubMed
40.
Torpy DJ, Tsigos C, Lotsikas AJ, Defensor R, Chrousos GP, Papanicolaou DA. Acute and delayed effects of a single-dose injection of interleukin-6 on thyroid function in healthy humans. Metabolism. 1998;47(10):1289–93.PubMedCrossRef
41.
Bartalena L, Brogioni S, Grasso L, Velluzzi F, Martino E. Relationship of the increased serum interleukin-6 concentration to changes of thyroid function in nonthyroidal illness. J Endocrinol Invest. 1994;17(4):269–74.PubMedCrossRef
42.
Yu J, Koenig RJ. Induction of type 1 iodothyronine deiodinase to prevent the nonthyroidal illness syndrome in mice. Endocrinology. 2006;147(7):3580–5.PubMedCrossRef
43.
Boelen A. Platvoet-Ter Schiphorst MC, Wiersinga WM. Soluble cytokine receptors and the low 3,5,3′-triiodothyronine syndrome in patients with nonthyroidal disease. J Clin Endocrinol Metab. 1995;80(3):971–6.PubMed
44.
Boelen A, Platvoet-Ter Schiphorst MC, Wiersinga WM. Association between serum interleukin-6 and serum 3,5,3′-triiodothyronine in nonthyroidal illness. J Clin Endocrinol Metab. 1993;77(6):1695–9.PubMed
45.
Rasmussen AK, Feldt-Rasmussen U, Bendtzen K. The effect of interleukin-1 on the thyroid gland. Autoimmunity. 1993;16(2):141–8.PubMedCrossRef
46.
Hamilton TA, Ohmori Y, Tebo JM, Kishore R. Regulation of macrophage gene expression by pro- and anti-inflammatory cytokines. Pathobiology. 1999;67(5–6):241–4.PubMedCrossRef
47.
van der Poll T, Romijn JA, Wiersinga WM, Sauerwein HP. Tumor necrosis factor: a putative mediator of the sick euthyroid syndrome in man. J Clin Endocrinol Metab. 1990;71(6):1567–72.PubMedCrossRef
48.
Stouthard JM, van der Poll T, Endert E, Bakker PJ, Veenhof CH, Sauerwein HP, et al. Effects of acute and chronic interleukin-6 administration on thyroid hormone metabolism in humans. J Clin Endocrinol Metab. 1994;79(5):1342–6.PubMed
49.
Tang KT, Braverman LE, DeVito WJ. Tumor necrosis factor-alpha and interferon-gamma modulate gene expression of type I 5′-deiodinase, thyroid peroxidase, and thyroglobulin in FRTL-5 rat thyroid cells. Endocrinology. 1995;136(3):881–8.PubMed
50.
Boelen A, Platvoet-ter Schiphorst MC, Bakker O, Wiersinga WM. The role of cytokines in the lipopolysaccharide-induced sick euthyroid syndrome in mice. J Endocrinol. 1995;146(3):475–83.PubMedCrossRef
51.
Hermus RM, Sweep CG, van der Meer MJ, Ross HA, Smals AG, Benraad TJ, et al. Continuous infusion of interleukin-1 beta induces a nonthyroidal illness syndrome in the rat. Endocrinology. 1992;131(5):2139–46.PubMed
52.
Boelen A, Platvoet-ter Schiphorst MC, Wiersinga WM. Immunoneutralization of interleukin-1, tumor necrosis factor, interleukin-6 or interferon does not prevent the LPS-induced sick euthyroid syndrome in mice. J Endocrinol. 1997;153(1):115–22.PubMedCrossRef
53.
Abilés J, de la Cruz AP, Castaño J, Rodríguez-Elvira M, Aguayo E, Moreno-Torres R, et al. Oxidative stress is increased in critically ill patients according to antioxidant vitamins intake, independent of severity: a cohort study. Crit Care. 2006;10(5):R146.PubMedCentralPubMedCrossRef
54.
Wajner SM, Goemann IM, Bueno AL, Larsen PR, Maia AL. IL-6 promotes nonthyroidal illness syndrome by blocking thyroxine activation while promoting thyroid hormone inactivation in human cells. J Clin Invest. 2011;121(5):1834–45.PubMedCentralPubMedCrossRef
55.
Menzies KJ, Robinson BH, Hood DA. Effect of thyroid hormone on mitochondrial properties and oxidative stress in cells from patients with mtDNA defects. Am J Physiol Cell Physiol. 2009;296(2):C355–62.PubMedCrossRef
56.
Henderson KK, Danzi S, Paul JT, Leya G, Klein I, Samarel AM. Physiological replacement of T3 improves left ventricular function in an animal model of myocardial infarction-induced congestive heart failure. Circ Heart Fail. 2009;2(3):243–52.PubMedCrossRef
57.
Forini F, Lionetti V, Ardehali H, Pucci A, Cecchetti F, Ghanefar M, et al. Early long-term L-T3 replacement rescues mitochondria and prevents ischemic cardiac remodelling in rats. J Cell Mol Med. 2011;15(3):514–24.PubMedCrossRef
58.
Klemperer JD, Klein I, Gomez M, Helm RE, Ojamaa K, Thomas SJ, et al. Thyroid hormone treatment after coronary–artery bypass surgery. N Engl J Med. 1995;333(23):1522–7.PubMedCrossRef
59.
Pingitore A, Galli E, Barison A, Iervasi A, Scarlattini M, Nucci D, et al. Acute effects of triiodothyronine (T3) replacement therapy in patients with chronic heart failure and low-T3 syndrome: a randomized, placebo-controlled study. J Clin Endocrinol Metab. 2008;93(4):1351–8.PubMedCrossRef
60.
Farwell AP. Thyroid hormone therapy is not indicated in the majority of patients with the sick euthyroid syndrome. Endocr Pract. 2008;14(9):1180–7.PubMedCrossRef
61.
Brent GA, Hershman JM. Thyroxine therapy in patients with severe nonthyroidal illnesses and low serum thyroxine concentration. J Clin Endocrinol Metab. 1986;63(1):1–8.PubMedCrossRef
62.
Becker RA, Vaughan GM, Ziegler MG, Seraile LG, Goldfarb IW, Mansour EH, et al. Hypermetabolic low triiodothyronine syndrome of burn injury. Crit Care Med. 1982;10(12):870–5.PubMedCrossRef
63.
Langouche L, Vander Perre S, Marques M, Boelen A, Wouters PJ, Casaer MP, et al. Impact of early nutrient restriction during critical illness on the nonthyroidal illness syndrome and its relation with outcome: a randomized, controlled clinical study. J Clin Endocrinol Metab. 2013;98(3):1006–13.PubMedCrossRef
64.
Plikat K, Langgartner J, Buettner R, Bollheimer LC, Woenckhaus U, Schölmerich J, et al. Frequency and outcome of patients with nonthyroidal illness syndrome in a medical intensive care unit. Metabolism. 2007;56(2):239–44.PubMedCrossRef
65.
Kaptein EM, Beale E, Chan LS. Thyroid hormone therapy for obesity and nonthyroidal illnesses: a systematic review. J Clin Endocrinol Metab. 2009;94(10):3663–75.PubMedCrossRef
66.
Debaveye Y, Ellger B, Mebis L, Visser TJ, Darras VM, Van den Berghe G. Effects of substitution and high-dose thyroid hormone therapy on deiodination, sulfoconjugation, and tissue thyroid hormone levels in prolonged critically ill rabbits. Endocrinology. 2008;149(8):4218–28.PubMedCentralPubMedCrossRef
67.
Lim VS, Tsalikian E, Flanigan MJ. Augmentation of protein degradation by l-triiodothyronine in uremia. Metabolism. 1989;38(12):1210–5.PubMedCrossRef
68.
Pappa TA, Vagenakis AG, Alevizaki M. The nonthyroidal illness syndrome in the non-critically ill patient. Eur J Clin Invest. 2011;41(2):212–20.PubMedCrossRef
69.
Villicev CM, Freitas FR, Aoki MS, Taffarel C, Scanlan TS, Moriscot AS, et al. Thyroid hormone receptor beta-specific agonist GC-1 increases energy expenditure and prevents fat-mass accumulation in rats. J Endocrinol. 2007;193(1):21–9.PubMedCrossRef
70.
van den Berghe G, Wouters P, Weekers F, Mohan S, Baxter RC, Veldhuis JD, et al. Reactivation of pituitary hormone release and metabolic improvement by infusion of growth hormone-releasing peptide and thyrotropin-releasing hormone in patients with protracted critical illness. J Clin Endocrinol Metab. 1999;84(4):1311–23.PubMed
71.
Debaveye Y, Ellger B, Mebis L, Van Herck E, Coopmans W, Darras V, et al. Tissue deiodinase activity during prolonged critical illness: effects of exogenous thyrotropin-releasing hormone and its combination with growth hormone-releasing peptide-2. Endocrinology. 2005;146(12):5604–11.PubMedCrossRef
72.
de Brito-Ashurst I, Varagunam M, Raftery MJ, Yaqoob MM. Bicarbonate supplementation slows progression of CKD and improves nutritional status. J Am Soc Nephrol. 2009;20(9):2075–84.PubMedCentralPubMedCrossRef
73.
Mahajan A, Simoni J, Sheather SJ, Broglio KR, Rajab MH, Wesson DE. Daily oral sodium bicarbonate preserves glomerular filtration rate by slowing its decline in early hypertensive nephropathy. Kidney Int. 2010;78(3):303–9.PubMedCrossRef
74.
Disthabanchong S, Treeruttanawanich A. Oral sodium bicarbonate improves thyroid function in predialysis chronic kidney disease. Am J Nephrol. 2010;32(6):549–56.PubMedCrossRef
75.
Brüngger M, Hulter HN, Krapf R. Effect of chronic metabolic acidosis on thyroid hormone homeostasis in humans. Am J Physiol. 1997;272:F648–53.PubMed
Metadaten
Titel
An update for the controversies and hypotheses of regulating nonthyroidal illness syndrome in chronic kidney diseases
Publikationsdatum
01.12.2014
Erschienen in
Clinical and Experimental Nephrology / Ausgabe 6/2014
Print ISSN: 1342-1751
Elektronische ISSN: 1437-7799
DOI
https://doi.org/10.1007/s10157-014-0974-1

Weitere Artikel der Ausgabe 6/2014

Clinical and Experimental Nephrology 6/2014 Zur Ausgabe

Original Article

Influence of conversion from calcineurin inhibitors to everolimus on fibrosis, inflammation, tubular damage and vascular function in renal transplant patients

Original Article

The role of a low glomerular density and being overweight in the etiology of proteinuria in CKD patients without known glomerular diseases

Commentary

A new xanthine oxidase inhibitor: the uric acid reduction and additional efficacy in CKD patients

Original Article

An association between serum γ-glutamyltransferase and proteinuria in drinkers and non-drinkers: a Japanese nationwide cross-sectional survey

Original Article

Derivation and validation of a risk score for contrast-induced nephropathy after cardiac catheterization in Chinese patients

Original Article

The problem of transition from pediatric to adult healthcare in patients with steroid-sensitive nephrotic syndrome (SSNS): a survey of the experts

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

24.04.2024 | DGIM 2024 | Kongressbericht | Nachrichten

Metformin rückt in den Hintergrund

24.04.2024 | DGIM 2024 | Kongressbericht | Nachrichten

Myokarditis nach Infekt – richtig schwierig wird es bei Profisportlern

24.04.2024 | DGIM 2024 | Kongressbericht | Nachrichten

Thrombophiliescreening – Wenn, dann richtig und nur bei therapeutischer Konsequenz

24.04.2024 | DGIM 2024 | Nachrichten

Bei Senioren mit Prostatakarzinom auf Anämie achten!
weitere anzeigen

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise